Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Kezar Life Sciences, Inc.
< Previous
1
2
Next >
Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023
March 06, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
March 03, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 06, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 13, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 07, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022
November 14, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
November 11, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
November 09, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting
November 03, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting
October 14, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
October 06, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis
October 03, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022
September 29, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
September 02, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 03, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position
July 11, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences to Present at the William Blair Biotech Focus Conference
July 07, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 06, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
June 27, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 03, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 05, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
May 03, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
April 15, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
March 17, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis
November 15, 2021
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.